Mehmet Eray ALÇIĞIR, Elvan ANADOL, Efe KARACA, Halit KANCA, Gül Fatma YARIM, Murat YARIM, Nilgün GÜLTİKEN

Malignant Meme Tümörlü Köpeklerde Plazma IGF-2 Konsantrasyonu ve Tümör Dokusundaki Ekspresyonu

Bu çalışmanın amacı, malignant meme tümörlü köpeklerde insülin benzeri büyüme faktörü-2 (IGF-2)'nin plazma konsantrasyonu ve tümör dokusundaki ekspresyonunu değerlendirmektir. Çalışmada toplam 15 köpek kullanıldı. Sekiz meme tümörlü köpek grup 1'i, 7 sağlıklı köpek ise grup 2'yi oluşturdu. Köpeklerin diöstrus döneminde oldukları vaginal sitolojik muayene ile belirlendi. Abdominal organların ultrasonografik muayenesi ve toraksın radyografik bakısı yapılarak metastaz değerlendirilmesi yapıldı. Köpeklerden kan örnekleri alındı, plazmaları elde edildi ve IGF-2 konsantrasyonu ELISA yöntemi ile belirlendi. Grup 1'de, tümörler "Dünya Sağlık Örgütü" (WHO)'nun belirlediği "Klinik Derecelendirme Sistemi"ne göre sınıflandırıldı ve komple unilateral mastektomi tekniğiyle uzaklaştırıldı. Tümörlerin histolojik olarak malignite derecesi Nottingham yöntemine göre tubul formasyonu, nüklear pleomorfizm ve mitotik hücre sayısına bağlı olarak değerlendirildi. Histopatolojik incelemelerde 4 karsinosarkom, 1 intraduktal papillar karsinom, 1 karsinom, 1 kompleks tip karsinom ve 1 miks tip karsinom tanısı konuldu. İmmunohistokimyasal incelemede tümör dokusunda meme asinus epitel hücreleri, miyoepitel hücreleri ve bazı damar düz kas hücrelerinde IGF-2 ekspresyonunun olduğu, duktus epitel hücrelerinde ise olmadığı gözlendi. Sağlıklı köpeklere göre, malignant meme tümörlü köpeklerde plazma IGF-2 konsantrasyonundaki artış istatistiksel olarak anlamlı bulundu (P?0.05).

Plasma IGF-2 Concentration and Tissue Expression in Dogs with Malignant

The aim of this study was to evaluate the plasma concentration of insulin like growth factor-2 (IGF-2) and its expression in tumor tissue of dogs with malignant mammary tumors. Fifteen dogs were used in the study. Eight dogs with mammary tumors constituted group 1, and 7 healthy dogs constituted group 2. Diestrus phase in dogs was determined with vaginal cytological examination. Metastasis was evaluated by ultrasonographic examination of abdomen and thorax radiography. Blood samples were collected from the dogs, plasma was separated and IGF-2 levels were measured with ELISA method. Tumors in group 1 were classified according to Clinical Grading System defined by World Health Organization and were removed by using complete unilateral mastectomy technique. The histological malignancy grading of tumors was made according tubule formation, nuclear pleomorphism, and number of mitotic cells by using Notthingham method. In histopathological examination, 4 carcinosarcoma, 1 intraductal papillary carcinoma, 1 carcinoma, 1 complex type carcinoma, and 1 mix type carcinoma were detected. In immunohistochemical investigation, IGF-2 expression was detected in mammary acinar epithelial cells, myoepithelial cells, and some vascular smooth muscle cells but not in ductal epithelial cells in tumor tissue. Compared to healthy dogs, the increase in plasma IGF-2 concentration in dogs with malignant mammary tumors was statistically significant (P?0.05).

PDF

___

1. Cohen D., Reif JS., Brodey RS., Keiser H., 1974. Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Research, 34, 2859- 2868.
2. Johnston SD., Kustritz MVR., Olson PNS., 2001. Canine and Feline Theriogenology. 1 st ed., 243- 256, Saunders, Philadelphia.
3. Illera JC., Pérez-Alenza MD., Nieto A., Jim´enez MA., Silvana G., Dunner S., Peña S., 2006. Steroids and receptors in canine mammary cancer. Steroids, 71, 541-548.
4. Queiroga FL., Pérez-Alenza MD., Silvan G., Peña L., Lopes C., Illera JC., 2005. Role of steroid hormones and prolactin in canine mammary cancer. Journal of Steroid Biochemistry & Molecular Biology, 94, 181-187.
5. Concannon P., Altszuler N., Hampshire J., Butler WR., Hansel W., 1980. Growth hormone, prolactin, and cortisol in dogs developing mammary nodules and an acromegaly-like appearance during treatment with medroxyprogesterone acetate. Endocrinology, 106, 1173.
6. Mol JA., van Garderen E., Selman PJ., Wolfswinkel J., Rijnberk A., Rutteman GR., 1995. Growth hormone mrna in mammary gland tumors of dogs and cats. Journal of Clinical Investigation, 95, 2028-2034.
7. Mol JA., van Garderen E., Rutteman GR., Rijnberk A., 1996. New insights in the molecular mechanism of progestin-induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. The Journal of Steroid Biochemistry and Molecular Biology, 57, 67-71.
8. Mol JA., Selman PJ., Sprang EP., van Neck JW., Oosterlaken-Dijksterhuis MA., 1997. The role of progestins, insulin-like growth factor (IGF) and IGF-binding proteins in the normal and neoplastic mammary gland of the bitch: a review. Journal of Reproduction and Fertilty Supplement, 51, 339-344.
9. Selman PJ., Mol JA., Rutteman GR., Rijnberk A.,1994. Progestin treatment in the dog. I. Effects on growth hormone, insulin-like growth factor I and glucose homeostasis. European Journal of Endocrinology , 131, 413-421.
10. Bergman D., Halje M., Nordin M., Engström W., 2013. Insulin-like growth factor 2 in development and disease: A mini-review. Gerontology, 59, 240-249.
11. Engström W., Shokrai A., Otte K., Granerus M., Gessbo A., Bierke P., Madej A., Sjolund M., Ward A., 1998. Transcriptional regulation and biological significance of the insulin like growth factor I1 gene. Cell Proliferation, 31, 173-189.
12. Samani AA., Yakar S., LeRoith D., Brodt P., 2007. The role of the ıgf system in cancer growth and metastasis: overview and recent ınsights. Endocrine Reviews, 28, 20-47.
13. Van Garderen E., Van der Poel HJA., Swennenhuis JF., Wissink EHJ., Rutteman GR., Hellmen E., Mol JA., Schalken JA., 1999. Expression and molecular characterization of the growth hormone receptor in canine mammary tissue and mammary tumors. Endocrinology, 140, 5907-5914.
14. Queiroga FL., Pérez-Alenza MD., Silvan G., Peña L., Lopes C., Illera JC., 2008. Crosstalk between GH/IGF-I axis and steroid hormones (progesterone, 17?-estradiol) in canine mammary tumours. Journal of Steroid Biochemistry & Molecular Biology, 110, 76-82.
15. Queiroga FL., Pérez-Alenza MD., Silvan G., Peña L., Lopes C., Illera JC., 2010. Serum and intratumoural GH and IGF-I concentrations: Prognostic factors in the outcome of canine mammary cancer. Research in Veterinary Science, 89, 396-403.
16. Kleinberg DL., 1998. Role of IGF-I in normal mammary development. Breast Cancer Research and Treatment, 47, 201-208.
17. Owen LN., 1980. TNM Classification of Tumours in Domestic Animals, 1st ed., 2-53, World Health Organization, Geneva.
18. Papanicolaou GN., 1942. A new procedure for staining vaginal smears. Science, 95,432.
19. Goldschmidt M., Pen~a L., Rasotto R., Zappulli V., 2011. Classification and grading of canine mammary tumors. Veterinary Pathology, 48, 117-131.
20. Elston CW., Ellis IO., 1998. Assessment of histological grade. In "The breast", Eds., CW Elston. IO Ellis., Vol. 13, 356-84, Churchill Livingstone, Edinburgh, New York.
21. Klopfleisch R., Hvid H., Klose P., da Costa A., Gruber AD., 2010. Insulin receptor is expressed in normal canine mammary gland and benign adenomas but decreased in metastatic canine mammary carcinomas similar to human breast cancer. Veterinary and Comparative Oncology, 8, 293-301.
22. Harbili S., 2008. İnsülin benzeri büyüme faktörleri (IGF): Egzersiz metabolizması ve kas dokusu üzerine etkileri. Genel Tıp Dergisi, 18, 177-184.
23. Mol JA., Lantinga-van Leeuwen IS., van Garderen E., Selman PJ., Oosterlaken-Dijksterhuis MA., Schalken JA., Rijnberk A., 1999. Mammary growth hormone and tumorıgenesıs-lessons from the dog. Veterinary Quarterly, 21, 111-115.
24. Peters MA., Mol JA., van Wolferen ME., Oosterlaken-Diksterhuis MA., Teerds KJ., van Sluijs FJ., 2003. Expressions of the insulin-like growth factor (IGF) system and steroidogenic enzymes in canine testis tumors. Reproductive Biology and Endocrinology, 14, 1-22.
25. Nosho K., Yamamoto H., Taniguchi H., Adachi Y., Yoshida Y., Arimura Y., Endo T., Hinoda Y., Imai K., 2004. Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, Cox-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis. Clinical Cancer Research, 10, 7950-7957.
26. Clemmons DR., 1997. Insulin-like growth factor binding proteins and their role in controlling ıgf actions. Cytokine & Growht Factor Reviews, 8, 45-62.
27. Keleş M., Türkeli M., 2005. İnsülin benzeri büyüme faktörü ve kanser. Tıp Araştırmaları Dergisi, 3, 39-43.
28. Yu H., Rohan T., 2009. Role of the insulin-like growth factor family in cancer development and progression. The Journal of the National Cancer Institute, 92, 1472-1489.
29. Bates P., Fisher R., Ward A., Richardson L., Hill DJ., Graham CF., 1995. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). British Journal of Cancer, 72, 1189-1193.
30. Rogler CE., Yang D., Rossettin L., Donohoe J., Alt E., Chang JC., Rosenfeld R., Neely K., Hintz R., 1994. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor II transgenic mice. The Journal of Biological Chemistry, 269, 13779-13784.
31. Beceriklisoy HB., Schafer-Somi S., Kucukaslan I., Agaoglu R., Gültiken N., Ay SS., Kaya D., Aslan S., 2009. Cytokines, growth factors and prostaglandin synthesis in the uterus of pregnant and non-pregnant bitches: the features of placental sites. Reproduction in Domestic Animals, 44, 115-119.
32. Lennard SN., Stewart F., Allen WR., 1995. Insulin like growth factor II gene expression in the foetus and placenta of the horse during the first half of gestation. Journal of Reproduction and Fertility, 103, 169-179.